# Clinical Trials Data KRAS - Document 49

# The Immunoscore as a Prognostic Marker for Patients With a Colorectal Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01688232

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Adult patient with newly diagnosed colorectal cancer.\n\* Patient with signed informed consent.\n\* Follow up made by the clinical center for inclusion or by a medical team in relation with the center.\n\nExclusion Criteria:",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Adult patient with newly diagnosed colorectal cancer.",

Question:  
Based on the following clinical trial information, would a patient with a KRAS gene mutation be eligible for the clinical trial?

Answer:  
This trial information \*\*doesn't say anything about KRAS mutation status\*\*, so we can't determine eligibility based on that factor. A patient \*might\* be eligible if they meet the other criteria (adult, newly diagnosed colorectal cancer, signed informed consent, appropriate follow-up), but the information provided is incomplete. KRAS mutation status is frequently used for inclusion or exclusion in colorectal cancer trials, so it's highly likely this trial has a criterion related to it that's simply not listed here. More information is needed.